ArticleCureus2025
Mirabegron Versus Tamsulosin in Reducing Double-J Stent-Related Symptoms: A Prospective Comparative Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Double-J (DJ) ureteral stents are widely used in endourology to relieve upper tract obstruction and ensure adequate postoperative drainage. However, stent-related symptoms (SRS), including lower urinary tract symptoms (LUTS), flank pain, haematuria, and discomfort, significantly impair patient quality of life. Pharmacologic interventions, such as alpha-blockers and beta-3 adrenergic agonists, have been proposed to mitigate SRS. This study aimed to compare the efficacy and safety of mirabegron versus tamsulosin in reducing DJ SRS. Materials and methods This prospective observational study was conducted at Shri B. M. Patil Medical College, Vijayapura, India (IEC No: BLDE (DU)/IEC/997/2022-23), between July 2023 and July 2024. A total of 130 adult patients with indwelling ureteral stents following endourological procedures were enrolled and allocated into two groups: Group A received tamsulosin 0.4 mg once daily, and Group B received mirabegron 50 mg once daily, continued until stent removal. Symptom assessment was performed at two and three weeks using the validated Ureteral Stent Symptom Questionnaire (USSQ). Safety profiles were also documented. Results Both groups demonstrated progressive symptom improvement over three weeks. Mirabegron showed significantly lower urinary symptom scores (12.1 vs. 15.6 at two weeks; 9.4 vs. 13.2 at three weeks, p < 0.001) and body pain scores (4.5 vs. 6.8 at two weeks; 3.1 vs. 5.4 at three weeks, p < 0.001). Improvements in general health, sexual function, and work performance favoured mirabegron, but were not statistically significant. Mirabegron exhibited a favourable safety profile, with fewer minor adverse events. Conclusions Mirabegron 50 mg once daily provides superior relief of urinary symptoms and pain compared to tamsulosin 0.4 mg once daily, with good tolerability and improved overall quality of life in patients with indwelling DJ ureteral stents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.